This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Chemotherapy-induced Nausea and Vomiting

This study has been completed.
Information provided by (Responsible Party):
Gunnar Birgegard, Uppsala University Hospital Identifier:
First received: April 9, 2010
Last updated: December 12, 2012
Last verified: December 2012
Delayed nausea is a common problem after high dose chemotherapy for bone marrow transplantation. This study wants to compare standard prophylactic anti-emetic therapy with the same treatment plus the drug aprepitant (Emend). The hypothesis is that addition of Emend will reduce nausea and vomiting.

Condition Intervention Phase
Nausea Vomiting Drug: Aprepitant (Emend) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study to Compare (EMEND®)to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients Undergoing Autologous Stem Cell Transplantation.

Resource links provided by NLM:

Further study details as provided by Gunnar Birgegard, Uppsala University Hospital:

Primary Outcome Measures:
  • Vomiting and nausea [ Time Frame: 7 days ]
    The proportion of patients with a complete response (no vomiting and/or only mild nausea and no use of rescue therapy) a/ during chemotherapy and b/ in the delayed phase (up to 7 days after end of chemotherapy).

Secondary Outcome Measures:
  • Safety and tolerability of the aprepitant regimen for CINV [ Time Frame: 3 weeks ]
    Possible side effects will be recorded, and all AE:s reported during 3 weeks after the chemotherapy.

Estimated Enrollment: 90
Study Start Date: May 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Standard antiemetic therapy plus placebo
Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
Drug: Placebo
Placebo will be administered instead of Emend
Experimental: aprepitant (Emend)
Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
Drug: Aprepitant (Emend)
Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
Other Name: Emend

Detailed Description:
A single centre randomized placebo-controlled phase II-study with a random assignment to experimental (EXP) or control (CTR) group. All patients with lymphoproliferative diseases ≥18 years of age, scheduled for myeloablative therapy before autologous stem cell transplantation at the Akademiska University Hospital in Uppsala, Sweden, will be included consecutively during one and a half year. A total of 90 patients (45 per treatment arm) will be accrued for this study. They will be invited by mail to participate in the study a couple of weeks before hospital entry. A random assignment to EXP or CTR will be performed by research nurses not participating in any other way in the study. Patients will be stratified for diagnosis which also means myeloablative therapy (lymphoma (BEAC) or myeloma (high-dose melphalan)), and the groups are expected to be similar in size. One box for each diagnosis (lymphoma and myeloma) will contain equal numbers of randomisation cards for the experimental and control groups, randomly mixed within each box. Cards will be picked consecutively by a research nurse not otherwise involved in the study. The EXP group will receive aprepitant (EMEND®) in combination with standard anti-emetic treatment and the CTR group will receive standard anti-emetic treatment. All treatment will be given in the hospital.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years
  • Able to communicate in Swedish
  • Diagnosis of lymphoproliferative disease
  • Scheduled for myeloablative therapy and autologous stem cell transplantation
  • Written informed consent
  • Able to swallow oral medications

Exclusion Criteria:

  • Nausea at baseline (immediately before start of chemotherapy)
  • Gastrointestinal obstruction or active peptic ulcer
  • Current illness requiring chronic systemic steroids or requirement for chronic use of antiemetic agent(s)
  • Hypersensitivity to any component of the study regimen
  • Pregnancy or nursing
  • Unrelenting hiccups
  • Radiation therapy to pelvis or abdomen within 1 week before or after study day 1
  • Psychiatric illness or multi-system organ failure
  • Hepatic insufficiency with ASAT, ALAT three times over reference value
  • Renal insufficiency with creatinin value three times over reference value.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01101529

Uppsala University Hospital
Uppsala, Sweden, 75185
Sponsors and Collaborators
Uppsala University Hospital
Principal Investigator: Gunnar Birgegard, MD, PhD University Hospital, Uppsala, Sweden
  More Information

Responsible Party: Gunnar Birgegard, Prof, Uppsala University Hospital Identifier: NCT01101529     History of Changes
Other Study ID Numbers: EudraCT nr: 2009-010545-31
2009-010545-31 ( EudraCT Number )
Study First Received: April 9, 2010
Last Updated: December 12, 2012

Keywords provided by Gunnar Birgegard, Uppsala University Hospital:
Chemotherapy-induced nausea and vomiting CINV

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017